SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Multiple sclerosis (MS)	CC chemokine receptor 4 (CCR4; CD194)	Mouse studies suggest inhibiting CCR4 on dendritic cells could help treat MS. In mice with experimental autoimmune encephalomyelitis (EAE), *Ccr4* knockout decreased disease severity and immune cell infiltration into the spinal cord compared with wild-type *Ccr4* expression. In the EAE model, *Ccr4* knockout mice that received intracerebral delivery of $Ccr4^{+/+}$ dendritic cells developed encephalomyelitis. Next steps could include developing inhibitors of CCR4 on dendritic cells. Kyowa Hakko Kirin Co. Ltd.'s mogamulizumab, a humanized mAb against CCR4, is under review to treat T cell lymphoma. Affitech A/S's CCR4 mAb, AT008, is in preclinical testing for cancer, autoimmune and inflammatory indications. *SciBX* 5(11); doi:10.1038/scibx.2012.275 Published online March 15, 2012	Findings unpatented; unavailable for licensing	Poppensieker, K. *et al.* *Proc. Natl. Acad. Sci. USA*; published online Feb. 21, 2012; doi:10.1073/pnas.1114153109 **Contact:** Judith Alferink, University of Bonn, Bonn, Germany e-mail: judith.alferink@ukb.uni-bonn.de